The present invention relates to the use of a peptide having the sequence of Formula I or a derivative thereof in preventing or treating liver damage, preferably relates to the use of the peptide or a derivative thereof in preventing or treating liver damage and Hepatitis C, €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒXaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4€ƒ€ƒ€ƒ€ƒ€ƒ(Formula I) wherein, Xaa1 is absent, Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is absent, Ala, Gly, Val, Leu, Ile or Pro. The invention also relates to a pharmaceutical composition comprising the peptide or a derivative thereof, a method of manufacturing the peptide and a polynucleotide encoding the peptide.